| Literature DB >> 30025795 |
Ozan Ötes1, Hendrik Flato2, Daniel Vazquez Ramirez2, Britta Badertscher3, Marc Bisschops4, Florian Capito5.
Abstract
The awareness about implementing continuous processing for biopharmaceutical products has significantly increased throughout the recent years not only at developmental scale but also for phase I supply in clinical trial manufacturing. In this study, we focused on upscaling continuous protein A chromatography from lab to pilot scale using the Cadence™ BioSMB PD and the Cadence™ BioSMB Process 80 system, respectively. Additionally, we evaluated hardware and software capability whilst running the system for 10 days non-stop using feed from a perfusion bioreactor. In terms of product quality and removal of impurities, comparable data was obtained regarding lab scale and production scale. Compared to batch mode, productivity was increased by 400 to 500%. Furthermore, the system worked accurately during the whole trial, proving its potential for the implementation into a hybrid or an end-to-end continuous process.Entities:
Keywords: Continuous chromatography; Downstream processing; Multi-column chromatography; Upscale
Mesh:
Substances:
Year: 2018 PMID: 30025795 DOI: 10.1016/j.jbiotec.2018.07.022
Source DB: PubMed Journal: J Biotechnol ISSN: 0168-1656 Impact factor: 3.307